Engineered therapeutic proteins for sustained-release drug delivery systems
- PMID: 37717712
- DOI: 10.1016/j.actbio.2023.09.018
Engineered therapeutic proteins for sustained-release drug delivery systems
Abstract
Proteins play a vital role in diverse biological processes in the human body, and protein therapeutics have been applied to treat different diseases such as cancers, genetic disorders, autoimmunity, and inflammation. Protein therapeutics have demonstrated their advantages, such as specific pharmaceutical effects, low toxicity, and strong solubility. However, several disadvantages arise in clinical applications, including short half-life, immunogenicity, and low permeation, leading to reduced drug effectiveness. The structure of protein therapeutics can be modified to increase molecular size, leading to prolonged stability and increased plasma half-life. Notably, the controlled-release delivery systems for the sustained release of protein drugs and preserving the stability of cargo proteins are envisioned as a potential approach to overcome these challenges. In this review, we summarize recent research progress related to structural modifications (PEGylation, glycosylation, poly amino acid modification, and molecular biology-based strategies) and promising long-term delivery systems, such as polymer-based systems (injectable gel/implants, microparticles, nanoparticles, micro/nanogels, functional polymers), lipid-based systems (liposomes, solid lipid nanoparticles, nanostructured lipid carriers), and inorganic nanoparticles exploited for protein therapeutics. STATEMENT OF SIGNIFICANCE: In this review, we highlight recent advances concerning modifying proteins directly to enhance their stability and functionality and discuss state-of-the-art methods for the delivery and controlled long-term release of active protein therapeutics to their target site. In terms of drug modifications, four widely used strategies, including PEGylation, poly amino acid modification, glycosylation, and genetic, are discussed. As for drug delivery systems, we emphasize recent progress relating to polymer-based systems, lipid-based systems developed, and inorganic nanoparticles for protein sustained-release delivery. This review points out the areas requiring focused research attention before the full potential of protein therapeutics for human health and disease can be realized.
Keywords: Long-term delivery systems; Nanoparticles; Protein therapeutics; Structural modification; Sustained release.
Copyright © 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Similar articles
-
Long-term delivery of protein therapeutics.Expert Opin Drug Deliv. 2015 Mar;12(3):415-40. doi: 10.1517/17425247.2015.961420. Epub 2014 Sep 24. Expert Opin Drug Deliv. 2015. PMID: 25251334 Free PMC article. Review.
-
Progress in nanoparticulate systems for peptide, proteins and nucleic acid drug delivery.Curr Pharm Biotechnol. 2011 Nov;12(11):1823-39. doi: 10.2174/138920111798377003. Curr Pharm Biotechnol. 2011. PMID: 21902630 Review.
-
Fabrication Of Dual pH/redox-Responsive Lipid-Polymer Hybrid Nanoparticles For Anticancer Drug Delivery And Controlled Release.Int J Nanomedicine. 2019 Oct 3;14:8001-8011. doi: 10.2147/IJN.S226798. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31632014 Free PMC article.
-
Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs.Ann Pharmacother. 2000 Jul-Aug;34(7-8):915-23. doi: 10.1345/aph.10054. Ann Pharmacother. 2000. PMID: 10928404 Review.
-
Implantable sustained-release drug delivery systems: a revolution for ocular therapeutics.Int Ophthalmol. 2023 Jul;43(7):2575-2588. doi: 10.1007/s10792-023-02637-x. Epub 2023 Jan 30. Int Ophthalmol. 2023. PMID: 36715956 Review.
Cited by
-
Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery.Int J Nanomedicine. 2024 Oct 1;19:10045-10064. doi: 10.2147/IJN.S479270. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39371476 Free PMC article. Review.
-
Advances in nanomaterials for precision drug delivery: Insights into pharmacokinetics and toxicity.Bioimpacts. 2024 Nov 2;15:30573. doi: 10.34172/bi.30573. eCollection 2025. Bioimpacts. 2024. PMID: 40256227 Free PMC article. Review.
-
Role of Oxidative Stress in Blood-Brain Barrier Disruption and Neurodegenerative Diseases.Antioxidants (Basel). 2024 Nov 28;13(12):1462. doi: 10.3390/antiox13121462. Antioxidants (Basel). 2024. PMID: 39765790 Free PMC article. Review.
-
Berberine and its derivatives: mechanisms of action in myocardial vascular endothelial injury - a review.Front Pharmacol. 2025 Mar 4;16:1543697. doi: 10.3389/fphar.2025.1543697. eCollection 2025. Front Pharmacol. 2025. PMID: 40103596 Free PMC article. Review.
-
Recombinant Hydrophobic Polypeptide MBAY Loaded Into SPION-Exosome Realizes Sustained-Release to Improve Type 2 Diabetes Mellitus.Drug Des Devel Ther. 2025 Apr 22;19:3103-3118. doi: 10.2147/DDDT.S499641. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40297314 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials